36 results about "Recurrent disease" patented technology

The invention describes methods and compositions for alleviating recurrent medical afflictions for which anxiety may cause or exacerbate the affliction. A subject suffering from the affliction is treated with a combination of a pharmaceutical that enhances learning, and a second pharmaceutical recognized to be useful for treatment of the affliction. Representative afflictions include insomnia, erectile dysfunction, female sexual dysfunction, neuropathic pain, attention deficit disorder, and depression.

The invention relates to an in-situ hybridization detection kit for platelet derived endothelial cell growth factor (PD-ECGF) genes, which comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is expressed as SEQ ID No.1. The invention also provides an in-situ hybridization detection method for the PD-ECGF genes. In addition, the invention also provides application of the kit in preparation a medicament for detecting early cancer transfer and recurrent diseases. The kit provided by the invention has the advantages of high sensitivity and strong specificity. The detection method is convenient and easy to operate, and can be universally used and popularized in hospitals of above district level.

Thymidylate synthase (TYMS) gene amplification was observed in 23% of 31 5-FU resistant liver metastases, while no amplification was observed in metastases of patients that had not been treated with 5-FU. Patients with metastases containing TYMS amplification had a substantially shorter median survival (329 days) than those without amplification (1021 days, p<0.01). Genetic amplification of TYMS has important implications for the management of colorectal cancer patients with recurrent disease.

The invention discloses an extcrnal antipruritic Chinese drug for curing the itch dermatoses, which is composed of 5 to 15 parts of shrubalthea bark, 15 to 30 parts of cnidium fruit, 5 to 10 parts of corktree bark, 5 to 10 parts of flavescent sophora root, 5 to 15 parts of root of paniculate swallowwort, 5 to 10 parts of dahurian angelica, 5 to 15 parts of Japanese ampelopsis, 5 to 10 parts of hyacinth bletilla, 15 to 30 parts of herb of Christina loosestrife, 10 to 15 parts of hairy vein agrimony, 10 to 15 parts of stemona Japonica Miq, 5 to 15 parts of capsule of weeping forsythia, 5 to 10 parts of common fenel, 15 to 30 parts of adsuki bean, 10 to 15 parts of knotweed and 10 to 15 parts of root-bark of densefruit ditany. The extcrnal Chinese drug for curing the itch dermatoses has the advantages of alleviating itch quickly, taking effect and curing fast, no scar at the skin damage position, convenient operation, no distress and toxic and side effects, etc. The patient can relieve itching in few seconds with the drug of the invention according to the clinical work, and can be cured without pains. The dermatoses of the acute disease can be cured in 1 to 3 days, and the chronic debilitated and recurrent disease can be cured in 1 to 3 monthes with matching with the Chinese drug for curing the itch dermatoses (internal and external application). The effective rate is 100 percent, the curative ratio is 100 percent, and the disease is not easy to be recurred after curing.

Disease cased by papilloma virus is treated by applying an effective amount of Mycobacterium to the region of infection. Specifically, condylomata acuminata are caused by human papilloma virus infection. Despite numerous treatment modalities these patients often demonstrate recurrent disease. BCG therapy is used in primary treatment or in patients not responding to or recurrent after standard treatment. Six men with rapidly recurrent external and intraurethral condylomata acuminata underwent BCG therapy after initial laser treatment. External application and intraurethral instillation of BCG was performed six times in weekly intervals. Follow-up studies included examination and endoscopic inspection of the urethra and bladder. Three patients completed one course of BCG and had no relapse of condylomata acuminata. Two patients underwent a second course of BCG, of whom one relapsed. One patient relapsed after discontinued therapy due to penile edema. The annual recurrence rate decreased from 3.2 before the BCG therapy to 0.75 after BCG therapy (p<0.05, test of equality of 2 percentages). In addition, eight men underwent BCG therapy as primary therapy without initial laser treatment, following the same course of treatment, but employing BCG in a cream with salicylic acid to promote keratolysis. Six out of eight patients completely recovered. The BCG-induced immune response appears to reduce the recurrence rate in patients with condylomata acuminata.

C. difficile infection (CDI) is the most common cause of antibiotic-associated diarrhea. Unfortunately, antibiotic therapy remains as the standard treatment for this antibiotic-induced disease and relapses are common. Antibiotic treatment typically is given for 10 to 14 days for initial or second episode of CDI. For recurrent episodes, more prolonged courses are recommended. It is disclosed herein that lower dose or shorter course of the antimicrobial treatment is sufficient to treat the disease and prevent recurrent disease by enabling a good immunologic response to infection, and perhaps also by better preserving normal flora, thus protecting against relapses or reinfection.

The present invention discloses a traditional Chinese medicine for treating gallstone and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine comprises the following ingredients in proportion by weight: 10-15 parts of spora lygodii, 10-15 parts of honeysuckle, 10-15 parts of mirabilite, 10-15 parts of radix curcumae, 10-15 parts of bitter orange, 10-15 parts of ginger, 10-15 parts of fructus forsythia, 10-15 parts of fresh babysbreath, 25-30 parts of Polygonum cuspidatum, 25-30 parts of Lysimachia christinae Hance, 25-30 parts of walnut, 5-8 parts of vitamin B6, 5-8 parts of trogopterus dung, 10-15 parts of pangolin, 25-30 parts of fried toosendan fruit, 10-15 parts of root of Mangnolia officinalis, 5-8 parts of liquorice and 25-30 parts of dendrobe. In the preparation method, the above medicinal materials are put in a freeze dryer for freezing and drying, grinded in fine powders, uniformly mixed with the mirabilite and vitamin B6 and finally encapsulated. The traditional Chinese medicine starts with the pathology of the gallstone, and has the advantages of enhancing the vitality of the organs, balancing the pH value of the blood, treating both symptoms and root causes and avoiding recurrent diseases after healing.

USP14 is a biomarker for recurrent disease and inhibition of USP14 is of therapeutic benefit for women with endometrial or ovarian cancer.

HER2+ invasive breast cancer (IBC) patients with residual disease following neoadjuvant chemotherapy have an anti-HER2 Type 1 T helper (Th1) cell immune deficit and a significant risk of recurrent disease. It has been shown that anti-HER2 CD4+ T-cell responses incrementally decrease along the breast cancer continuum - a robust response in healthy donors and patients with benign disease, a depressed response in patients with HER2+ ductal carcinoma in situ, and a nearly absent response in patients with HER2+ IBC. This invention relates to a method of creating a microenvironment for culture expansion of T cells. The expanded T cells can be used for a variety of therapeutic and research purposes.

The present invention describes methods for determining the risk that a breast precursor lesion will progress to invasive breast cancer and/or the risk of recurrent non-invasive disease in a patient, comprising detecting the presence and/or level of PAPPA and/or PAPPA functional activity in a breast tissue sample obtained from the patient, wherein if PAPPA is not present, or is present at a reduced amount compared to a control, there is the risk of progression to invasive cancer and/or the risk or recurrent disease.

The present invention also enables the chemosensitisation of mitotically delayed breast cancer cells to anti-proliferative agents, preferably anti-mitotic agents, by restoring normal progression through mitosis. In this embodiment a first drug is applied to release breast cancer cells from the mitotic block and, sequentially, a second drug affecting proliferating cells is administered for cancer cell killing.

The invention relates to an in-situ hybridization testing kit of a KAI1 gene. The kit comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is shown as SEQ ID No. 1. The invention also provides an in-situ hybridization testing method of the KAI1 gene. In addition, the invention also provides application of the kit to preparation of medicaments for testing cancer early transfer and recurrent diseases. The kit provided by the invention has the characteristics of high flexibility and specificity. The testing method of the invention is convenient and easy to operate and can be generally used and popularized in district-level or city-level hospitals.

The invention relates to a mushroom king snail delicacy dietotherapy special food with a significant anti-cancer effect and a preparation method thereof. The special food is mainly composed of the following raw materials in parts by weight: 45-50 parts by weight of grifola frondosa, 20-25 parts by weight of flower mushrooms, 15-20 parts by weight of snails, 20-25 parts by weight of puffer, 15-20 parts by weight of shark liver and stomach, 10-15 parts by weight of black clam meat, 70-75 parts by weight of konjac surimi wonton, 95-100 parts by weight of nutritive soup stock with a plurality of tastes, and 0.8-1.2 parts by weight of nisin. The special food has stronger curative effect than anti-cancer agents. The raw materials of the product are prepared from natural creatures, and a plurality of both medicinal and edible food materials with special nutrients and special functions. The materials are rich in more than 20 effective anti-cancer elements, and have obvious dietotherapy specialeffects and auxiliary anti-cancer effects of resisting and treating middle-stage or advanced-stage recurrent diseases such as intestinal cancer, uterus cancer, breast cancer, ovarian cancer, prostatecancer, esophageal cancer, skin cancer, bladder cancer, stomach cancer, liver cancer, lung cancer and malignant lymphoma, and can also improve the overall nutritional advantages of cancer patients.

The invention relates to an MMP2 gene in-situ hybridization detection kit, which comprises a hybridization probe and markers, wherein the sequence of the hybridization probe is represented by the sequence SEQ ID No.1. The invention also provides an MMP2 gene in-situ hybridization detection method and the use of the kit in the preparation of medicaments for detecting cancer early transfer and recurrent diseases. The invention has the advantage that the kit provided by the invention has the characteristics of high sensitivity and high specificity. The detection method of the invention is convenient and simple for operation and can be widely used and promoted in district or above hospitals.

The invention relates to an in-situ hybridization testing kit of a chemically activated receptor CXCR4 gene. The kit comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is shown as SEQ ID No. 1. The invention also provides an in-situ hybridization testing method of the CXCR4 gene. In addition, the invention also provides application of the kit to preparation of medicaments for testing cancer early transfer and recurrent diseases. The kit provided by the invention has the characteristics of high flexibility and specificity. The testing method of the invention is convenient and easy to operate and can be generally used and popularized in district-level or city-level hospitals.

The invention relates to an in situ hybridization detection kit for cancer antigen 105 (CD105) genes. The in situ hybridization detection kit for the CD105 genes comprises a hybridization probe and a marker, wherein the sequence of the hybridization probe is shown as SEQ ID NO.1. The invention also provides an in situ hybridization detection method for the CD105 genes. In addition, the invention also provides application of the kit to preparation of medicaments for detecting cancer early transfer and recurrent diseases. The kit provided by the invention has the characteristics of high sensitivity and high specificity. The detection method of the invention is convenient and simple in operation and can be commonly used and popularized in hospitals above district level.

The invention discloses egg-laying duck fodder capable of improving egg yield. The egg-laying duck fodder comprises, by weight, 8-16 parts of vegetables, 5-13 parts of locust tree powder, 25-33 parts of fructus psoraleae, 13-21 parts of fructus cnidii, 24-32 parts of glossy privet fruit, 22-30 parts of mirabilite, 26-34 parts of ligusticum wallichii, 17-25 parts of fructus choerospondiatis and 20-28 parts of herba aristolochiae. By rational combination, the egg-laying duck fodder prepared by adopting the modern science and technology can promote comprehensive assimilation of egg-laying duck nutrition; by controlling proportion of ingredients in the fodder, conversion rate of the fodder can be effectively increased, some recurrent diseases of egg-laying ducks are prevented, immunity of the ducks is improved, and consequently egg laying of the ducks can be improved. In addition, the ducks fed by the fodder can lay higher-quality eggs.

The invention discloses a pharmaceutical composition for regulating immunity balance and application thereof. The pharmaceutical composition is prepared from, by mass, 1-5 parts of rhizoma zingiberis, 1-5 parts of fructus evodiae, 1-5 parts of fructus toosendan, 1-5 parts of rhizoma coptidis, 1-10 parts of cortex cinnamomi, 1-10 parts of rhizoma anemarrhenae, 1-10 parts of fructus amomi and 1-10 parts of raw radix glycyrrhizae. The pharmaceutical composition disclosed by the invention can regulate the immunity balance of the human body, prevent and assist in treating common internal medicine diseases, and common diseases among female and children, reduce the frequency of attack of recurrent diseases such as pediatric susceptibility, dysmenorrhea, and menstrual disorder, shorten the treatment period for rhinitis, pediatric growth retardation, hyperactivity and twitch, anorexia, constipation, myopia, adult insomnia and other diseases with a protracted course, can stop drugs for controlling symptoms through continuous oral administration as soon as possible, and has a significant effect.